Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?
Federici
A B
AB
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine and Medical Specialties, IRCCS Foundation Maggiore Policlinico Hospital, Mangiagalli, Regina Elena and University of Milan, Milan, Italy. augusto.federici@unimi.it
D000941:Antigens / Q000032:analysis; D001327:Autoimmune Diseases / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D002318:Cardiovascular Diseases / Q000150:complications; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D019468:Disease Management; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008232:Lymphoproliferative Disorders / Q000150:complications; D009196:Myeloproliferative Disorders / Q000150:complications; D009369:Neoplasms / Q000150:complications; D011446:Prospective Studies; D012042:Registries; D014842:von Willebrand Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000276:immunology / Q000628:therapy; D014841:von Willebrand Factor / Q000032:analysis
D000941:Antigens; D007166:Immunosuppressive Agents; C029417:Von Willebrand antigen; D014841:von Willebrand Factor; D003894:Deamino Arginine Vasopressin